These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

346 related articles for article (PubMed ID: 22079193)

  • 1. Human T-cell responses to botulinum neurotoxin. Responses in vitro of lymphocytes from patients with cervical dystonia and/or other movement disorders treated with BoNT/A or BoNT/B.
    Oshima M; Deitiker PR; Jankovic J; Duane DD; Aoki KR; Atassi MZ
    J Neuroimmunol; 2011 Dec; 240-241():121-8. PubMed ID: 22079193
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Human T-cell responses to botulinum neurotoxin: proliferative responses in vitro of lymphocytes from botulinum neurotoxin A-treated movement disorder patients.
    Oshima M; Deitiker PR; Jankovic J; Duane DD; Aoki KR; Atassi MZ
    J Neuroimmunol; 2011 Aug; 237(1-2):66-72. PubMed ID: 21737146
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Regions on the Light Chain of Botulinum Neurotoxin Type A Recognized by T Cells from Toxin-Treated Cervical Dystonia Patients. The Complete Human T-Cell Recognition Map of the Toxin Molecule.
    Oshima M; Deitiker P; Jankovic J; Atassi MZ
    Immunol Invest; 2018 Jan; 47(1):18-39. PubMed ID: 28891721
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular immune recognition of botulinum neurotoxin B. The light chain regions that bind human blocking antibodies from toxin-treated cervical dystonia patients. Antigenic structure of the entire BoNT/B molecule.
    Atassi MZ; Jankovic J; Steward LE; Aoki KR; Dolimbek BZ
    Immunobiology; 2012 Jan; 217(1):17-27. PubMed ID: 21962573
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mapping of the regions on the heavy chain of botulinum neurotoxin A (BoNT/A) recognized by antibodies of cervical dystonia patients with immunoresistance to BoNT/A.
    Dolimbek BZ; Aoki KR; Steward LE; Jankovic J; Atassi MZ
    Mol Immunol; 2007 Feb; 44(5):1029-41. PubMed ID: 16647121
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Botulinum toxin type B in antibody-induced botulinum toxin type A therapy failure.
    Dressler D; Bigalke H; Benecke R
    J Neurol; 2003 Aug; 250(8):967-9. PubMed ID: 12928917
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Botulinum toxin type B vs. type A in toxin-naïve patients with cervical dystonia: Randomized, double-blind, noninferiority trial.
    Pappert EJ; Germanson T;
    Mov Disord; 2008 Mar; 23(4):510-7. PubMed ID: 18098274
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunogenicity and long-term efficacy of botulinum toxin type B in the treatment of cervical dystonia: report of 4 prospective, multicenter trials.
    Chinnapongse RB; Lew MF; Ferreira JJ; Gullo KL; Nemeth PR; Zhang Y
    Clin Neuropharmacol; 2012; 35(5):215-23. PubMed ID: 22932474
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evidence-based review and assessment of botulinum neurotoxin for the treatment of movement disorders.
    Hallett M; Albanese A; Dressler D; Segal KR; Simpson DM; Truong D; Jankovic J
    Toxicon; 2013 Jun; 67():94-114. PubMed ID: 23380701
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dynamic cortical gray matter volume changes after botulinum toxin in cervical dystonia.
    Delnooz CC; Pasman JW; van de Warrenburg BP
    Neurobiol Dis; 2015 Jan; 73():327-33. PubMed ID: 25447226
    [TBL] [Abstract][Full Text] [Related]  

  • 11. British Neurotoxin Network recommendations for managing cervical dystonia in patients with a poor response to botulinum toxin.
    Marion MH; Humberstone M; Grunewald R; Wimalaratna S
    Pract Neurol; 2016 Aug; 16(4):288-95. PubMed ID: 26976927
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Submolecular recognition regions of the H
    Oshima M; Deitiker P; Jankovic J; Atassi MZ
    J Neuroimmunol; 2016 Nov; 300():36-46. PubMed ID: 27806874
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Use of botulinum neurotoxin therapy].
    Mukai Y; Kaji R
    Brain Nerve; 2011 Jul; 63(7):775-84. PubMed ID: 21747148
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cross reaction of tetanus and botulinum neurotoxins A and B and the boosting effect of botulinum neurotoxins A and B on a primary anti-tetanus antibody response.
    Dolimbek BZ; Jankovic J; Atassi MZ
    Immunol Invest; 2002; 31(3-4):247-62. PubMed ID: 12472183
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-responsive cervical dystonia.
    Brashear A; Lew MF; Dykstra DD; Comella CL; Factor SA; Rodnitzky RL; Trosch R; Singer C; Brin MF; Murray JJ; Wallace JD; Willmer-Hulme A; Koller M
    Neurology; 1999 Oct; 53(7):1439-46. PubMed ID: 10534248
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Factors influencing secondary non-response to botulinum toxin type A injections in cervical dystonia.
    Ferreira JJ; Colosimo C; Bhidayasiri R; Marti MJ; Maisonobe P; Om S
    Parkinsonism Relat Disord; 2015 Feb; 21(2):111-5. PubMed ID: 25499753
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of specific immune responses to BoNT/A and tetanus toxoid in patients undergoing treatment for neurologic disorders.
    Vlata Z; Tsatsakis A; Tzagournissakis M; Krambovitis E
    Endocr Metab Immune Disord Drug Targets; 2012 Sep; 12(3):268-73. PubMed ID: 22385115
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-resistant cervical dystonia.
    Brin MF; Lew MF; Adler CH; Comella CL; Factor SA; Jankovic J; O'Brien C; Murray JJ; Wallace JD; Willmer-Hulme A; Koller M
    Neurology; 1999 Oct; 53(7):1431-8. PubMed ID: 10534247
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of botulinum toxin serotypes A and B for the treatment of cervical dystonia.
    Comella CL; Jankovic J; Shannon KM; Tsui J; Swenson M; Leurgans S; Fan W;
    Neurology; 2005 Nov; 65(9):1423-9. PubMed ID: 16275831
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An analysis of the efficacy of botulinum neurotoxin type a in treating cervical dystonia.
    Zhou X; Li ZF; Guo XZ; Wei Q; Niu YN; Li M; Xia JN; Chen LP
    Technol Health Care; 2024; 32(4):2421-2430. PubMed ID: 38073352
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.